Brief: Cartesian Therapeutics Inc - Phase 3 Aurora Topline Data In Myasthenia Gravis Expected In 1Q27 BLA Filing Planned Mid-2027
26/05/2026 12:09
May 26 (Reuters) - Cartesian Therapeutics Inc RNAC.O: CARTESIAN THERAPEUTICS SECURES UP TO $150 MILLION OF NON-DILUTIVE FINANCING FROM K2 HEALTHVENTURES AND EXPECTS TOPLINE DATA FROM THE PHASE 3 AURORA TRIAL IN FIRST QUARTER 2027 CARTESIAN THERAPEUTICS INC - PHASE 3 AURORA TOPLINE DATA IN MYASTHENIA GRAVIS EXPECTED IN 1Q27; BLA FILING PLANNED MID-2027 Source text: ID:nGNX6rTrQD Further company coverage: RNAC.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cartesian Therapeutics
See all newsBrief: Cartesian Therapeutics Announces Additional Retreatment Data For Descartes-08 Highlighting Deep And Durable Responses In Patients With Myasthenia Gravis
Cartesian Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Cartesian Therapeutics Q2 net income steady
Brief: Cartesian Therapeutics Inc Q2 Net Income USD 15.769 Million
Cartesian Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview